Navigation Links
Nektar Therapeutics Reports First Quarter 2011 Financial Results
Date:4/27/2011

p>

11,29933,237Operating costs and expenses:   Cost of goods sold

3,2634,296   Research and development

30,17623,286   General and administrative

11,7279,013Total operating costs and expenses

45,16636,595Loss from operations

(33,867)(3,358)Non-operating income (expense):Interest income

432463Interest expense

(2,585)(2,951)Other income, net

13424Total non-operating expense

(2,019)(2,464)Loss before provision for income taxes

(35,886)(5,822)Provision for income taxes

148308Net loss

$ (36,034)$ (6,130)Basic and diluted net loss per share

$
(0.33)$   (0.07)Weighted average shares used in computing basic and diluted net loss per share

108,67793,631NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)(unaudited)Three Months Ended March 31,20112010Cash flows from operating activities:Net loss

$   (36,034)$   (6,130)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization

3,8564,149Stock-based compensation

4,8023,744Other non-cash transactions

309(235)Changes in operating assets and liabilities:Accounts receivable

22,942(2,908)Inventory

(4,446)(2,232)Other assets

(1,199)(883)Accounts payable

(2,895)1,748Accrued compensation

(1,572)(4,348)Accrued expenses

1,9611,354Accrued clinical trial expenses

1,505(552)Deferred revenue

(2,555)(26,568)Other liabilities

(1,544)(1,302)Net cash used in operating activities

$   (14,870)$ (34,163)Cash flows from investing activities:Purchases of investments

(372,723)(115,277)Maturities of investments

113,235112,074Sales of investments

61,3688,197Purchases of property and equipment

(3,765)(3,973)Net cash (used in) provided by investing activities

$ (201,885)$
,021Cash flows from financ
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Dennis Winger Joins Nektar Therapeutics Board of Directors
2. Nektar Therapeutics Reports Third Quarter 2009 Financial Results
3. Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets
4. Nektar Therapeutics to Host Conference Call to Discuss Todays Announcement of a New Partnership for NKTR-118 and NKTR-119
5. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
6. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
7. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
8. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
9. Nektar Therapeutics Reports First Quarter 2009 Financial Results
10. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
11. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Pipette.com has added the ... their comprehensive portfolio of Eppendorf products. , The Eppendorf ... a Centrifuge 5424/5424 R and receive the following:, ... Research plus or Eppendorf Reference 2 , ...
(Date:1/22/2015)... Denville, NJ (PRWEB) January 22, 2015 ... shearing technologies such as the Bioruptor® and complete ... semi-automation system for chromatin immunoprecipitation, alleviating the need ... reagents and controls needed for ChIP of histones ...
(Date:1/22/2015)... N.J. , Jan. 22, 2015  Derma Sciences, ... regeneration company focused on advanced wound care, announces ... placental tissues, have been added to the Premier, ... increases the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® ...
(Date:12/24/2014)... BioLife Solutions , Inc. (NASDAQ: BLFS ), a ... hypothermic storage and cryopreservation freeze media and ... ("BioLife" or the "Company"), today announced that it will hold ... (the "Annual Meeting"). Because the expected date for ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... 7 Odyssey Thera, Inc. announced,that it has ... decision to progress a discovery stage drug candidate ... by,Odyssey Thera as part of the ongoing collaboration ... the progress of the collaboration with,Pfizer," said John ...
... Aug. 7 AutoImmune Inc. (OTC,Pink Sheets: AIMM) today reported ... diluted, for the three months ended June 30, 2008, compared ... basic and diluted, for the,three months ended June 30, 2007. ... was $193,000, or $0.01 per share basic and diluted, compared,with ...
... (Nasdaq: KERX ) will hold a conference call ... discuss the second quarter 2008 financial results.,Michael S. Weiss, ... the call. Keryx will announce its financial results for ... to the call., In order to participate in ...
Cached Biology Technology:AutoImmune Inc. Reports 2008 Second Quarter Financial Results 2AutoImmune Inc. Reports 2008 Second Quarter Financial Results 3Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT 2
(Date:1/22/2015)... 2015  Today, FreeWavz ( www.FreeWavz.com ), the developer ... on Fundable, https://www.fundable.com/freewavz . FreeWavz will be ... to meet customer demand. Logo - ... Invented by Dr. ...
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... technology and tech stocks, releases video from the CES 2015 ... security consultant Apollo Robbins . Apollo shows ... Wocket™ biometric smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
(Date:1/22/2015)... has launched its new NXG series of time clocks with ... higher standard for collecting attendance and labor data and complements ... touch screen interface and seamless connection to cloud-based iSolved, the ... for the small to mid-size employer. The G2 ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Infinisource's NXG series sets new time clock standard 2
... This week, research was published showing that silk produced ... Jr., professor of biological sciences at University of Notre ... spider silk. This stronger silk could possibly be used ... findings were published in the Proceedings of the ...
... Sciences Research Council have shown one way in which poor ... risk of developing type 2 diabetes and other age-related diseases ... of identifying people who are at a higher risk of ... The team, from the University of Cambridge and the ...
... for taxonomic studies on the members of the ginger family (Zingiberaceae) ... University of Calicut , have resulted in the discovery of an ... Park on the Western Ghats of Kerala. The ginger ... which are widely used as spices, for medical purposes, or simply ...
Cached Biology News:Hybrid silkworms spin stronger spider silk 2How poor maternal diet can increase risk of diabetes -- new mechanism discovered 2How poor maternal diet can increase risk of diabetes -- new mechanism discovered 3
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
... Clone/PAD: ZMD.283. Immunogen: Fusion ... Specificity: Specific for ASIP/PAR-3 (atypical PKC ... This antigen is not related to ... Reactivity: Human Dog Xenopus (positive controls: ...
...
Request Info...
Biology Products: